Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VOB560 |
| Synonyms | |
| Therapy Description |
VOB560 binds to and selectively inhibits Bcl2, potentially leading to induction of apoptosis and inhibition of tumor cell proliferation (Cancer Res 2021;81(13_Suppl):Abstract nr 1276). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VOB560 | S 65487|S-65487|S65487|VOB 560|VOB-560 | BCL2 inhibitor 29 | VOB560 binds to and selectively inhibits Bcl2, potentially leading to induction of apoptosis and inhibition of tumor cell proliferation (Cancer Res 2021;81(13_Suppl):Abstract nr 1276). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |